# A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

> **NCT02513550** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1257 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02513550
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-11
- **Final completion:** 2017-08-03
- **Target enrollment:** 1257 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513550, "A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02513550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*